Delivery Order 36F79718D0566-36C26025F0084
Award Date
11/13/24
Potential Completion Date
2/13/25
Potential Value
$43K
Federal Agency
Veterans Integrated Service Network 20
Awardee
Biogen U.s. Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02142, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Biogen U.S. Corporation is for the delivery of the pharmaceutical product QALSODY (tofersen) to the U.S. Department of Veterans Affairs (VA). The $21,738.30 firm fixed price delivery order is placed against Biogen's Pharmaceuticals and Drugs GSA Schedule contract. The contract has no set-aside designation, indicating Biogen competed against other vendors to secure this award. Biogen U.S. Corporation is a subsidiary of Biogen Idec Incorporated that focuses on...
The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm-fixed-price delivery order to Biogen U.S. Corporation, a pharmaceutical manufacturer, for the supply of QALSODY and QALSODY (TOFERSEN) 6.7MG SOLN. This $43,476.60 order was placed against Biogen's Pharmaceuticals and Drugs GSA Schedule contract and will be delivered by June 1, 2024. Biogen also holds a $11.39 million single-award indefinite delivery contract with the VA National Acquisition Center to provide...
This federal contract award is for the delivery of QALSODY (TOFERSEN) 6.7MG SOLN (2 VIALS) NDC: 64406-0109-01 pharmaceutical product to the Department of Veterans Affairs (VA). The contract was awarded to Biogen U.S. Corporation, a subsidiary of Biogen Idec Incorporated, a biotechnology company focused on developing therapies for neurological diseases. The contract is a firm-fixed-price delivery order valued at $21,738.30, awarded against Biogen's Pharmaceuticals and Drugs General Services...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a $10,869.15 delivery order to Biogen U.S. Corporation under the company's Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule contract. The firm fixed price order is for QALSODY (TOFERSEN) 6.7MG SOLN NDC: 64406-0109-01, with an anticipated completion date of April 13, 2024. Place of performance will be in Cambridge, Massachusetts. No set-aside designation was used for this order....
This federal contract award is a firm fixed-price delivery order issued by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The contract, valued at $485,835.00, is for the supply of DALFAMPRIDINE 100 MG, a medication used to treat Parkinson's disease and multiple sclerosis symptoms. The contract was awarded on January 17, 2017, with a final completion date of...
This is a firm fixed-price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of therapies for neurological disorders. The contract is for the supply of DALFAMPRIDINE, a medication used to treat Parkinson's disease and multiple sclerosis symptoms. The contract, valued at $478,860.00, is under the VA's Federal Supply Schedule 61-IB - Pharmaceuticals and Drugs....
This is a $382,300.88 firm fixed-price delivery order contract awarded by the Veterans Integrated Service Network 20 (VISN 20) of the U.S. Department of Veterans Affairs (VA) to Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing drugs for rare diseases. The contract is for the bulk order of ORLADEYO, a drug used to treat hereditary angioedema, to support veteran healthcare. The contract is not set aside and is part of Biocryst's Federal Supply Schedule (FSS)...
This is a federal contract award from the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company specializing in neurological disorder treatments. The contract is a Delivery Order against Acorda's existing Federal Supply Schedule (FSS) contract with the VA, valued at over $16.3 million and expiring in September 2024. This specific award, valued at $861,948.00, is for the supply of DALFAMPRIDINE, a medication used to treat Parkinson's disease symptoms....
This federal contract award, valued at $95,772.00, was issued by the Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company specializing in neurological therapies. The contract is a delivery order under Acorda's Federal Supply Schedule (FSS) contract with the VA, which has a total value of over $16.3 million and is used to procure the company's pharmaceutical products, including Levodopa 42mg inhalation capsules for the treatment of Parkinson's disease. The...
This is a delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The contract is for the supply of Dalfampridine 10mg sustained-action (SA) tablets, a medication used to treat multiple sclerosis. The contract has a ceiling value of $485,835.00 and is a firm fixed-price delivery order, with no set-aside designation. This contract...